ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome

Orignal Post here ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events reported Two pivotal Phase 2/3 trials are expected to start by the end of 2021 Management to host a conference call today at 8:15am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass.,
Read

When touching is forbidden

When I was 18 years I was diagnosed with Usher Syndrome and it took me another eighteen years to understand which were the consequences of this disease and realize that it is one of the main causes of deaf blindness.
Read